News

Bitwise Introduces a Premier Solana Staking ETP for Investors

Bitwise Introduces a Premier Solana Staking ETP for Investors

Introducing the Bitwise Solana Staking ETP

Investors seeking opportunities in the cryptocurrency market can look forward to the newly launched Bitwise Solana Staking ETP (BSOL). This innovative product is tailored specifically for those wanting to earn rewards from SOL staking, utilizing a cutting-edge staking mechanism to ensure the best possible outcomes.

Continued Growth in Crypto Assets

Bitwise has marked its presence in the crypto sector with this launch, which is the third staking ETP introduced within a single year, following the successful introductions of Ethereum and Aptos staking ETPs. This strategic move further solidifies Bitwise's role as a pivotal player in the expanding crypto asset market, offering top-tier investment vehicles that cater to the evolving needs of institutional investors.

Understanding Solana's Role in Blockchain

Solana is rapidly establishing itself as a leading force in the blockchain domain, admired for its unmatched transaction speeds and scalability. It competes directly with Ethereum, emerging as a preferred platform not only for smart contracts but also for NFTs. With its unique architecture, Solana can handle up to 65,000 transactions every second, making it an optimal choice for retail users and high-demand applications.

The Benefits of the Bitwise Solana Staking ETP

BSOL stands out in the marketplace for its full backing in Germany and its commitment to delivering high staking returns with minimal total ownership costs. Unlike other products available, BSOL is uniquely benchmarked against the Compass Solana Total Return Monthly Index (SOLTRM), fostering transparency and clarity in performance evaluations for investors. Furthermore, it is primary listed on Deutsche Börse XETRA, thus providing European investors with an understandable and liquid investment option featuring staked SOL exposure.

Hunter Horsley, the CEO and Co-Founder of Bitwise, stated, “We continue to expand our offerings to ensure investors have access to reliable crypto opportunities. The launch of BSOL marks an exciting chapter for us as it's our third staking ETP this year. We are proud to place Solana amongst our premier offerings.”

Understanding Staking and Its Rewards

In the context of a proof-of-stake blockchain like Solana, token holders can stake their assets to help validate transactions, thereby contributing to overall network security. This action allows them to earn additional tokens as rewards, similar to receiving dividends. However, only those who actively delegate their SOL to validators can partake in these rewards.

Bitwise's Remarkable Growth Journey

Throughout the year, Bitwise has experienced substantial growth, with total client assets surpassing $12 billion. The introduction of BSOL reflects the company’s ongoing commitment to enhancing its product offerings in Europe, particularly following the acquisition of a premier crypto asset manager. This aligns with Bitwise’s broader strategy to innovate within the European crypto market, guaranteeing that products not only remain relevant but also deliver superior performance.

Core Details of the Bitwise Solana Staking ETP

For those contemplating investments, some key product details include:

  • ETP Name: Bitwise Solana Staking ETP
  • Primary Ticker: BSOL
  • ISIN: DE000A4A59D2
  • TER: 0.85% p.a.
  • Underlying Asset Class: Digital Assets
  • Strategy: Staked SOL Total Return
  • Primary Listing: Deutsche Börse XETRA
  • Issuer: Bitwise Europe GmbH

Frequently Asked Questions

What is the Bitwise Solana Staking ETP?

The Bitwise Solana Staking ETP (BSOL) is a product designed to provide investment exposure to the rewards earned from staking Solana’s cryptocurrency, SOL.

Why should I consider investing in BSOL?

Investing in BSOL offers the potential for high staking returns and access to the rapidly growing Solana blockchain ecosystem.

Does BSOL have any benchmarks?

Yes, BSOL is benchmarked against the Compass Solana Total Return Monthly Index, ensuring transparency in its performance metrics.

Is the Bitwise Solana Staking ETP fully backed?

Yes, BSOL is fully backed and issued in Germany, focusing on providing the highest staking returns for investors.

What has contributed to Bitwise's growth this year?

Bitwise's growth is attributed to the launch of strategic products, including BSOL, and the acquisition of a leading crypto asset manager, enhancing its position in the market.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 230

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 225

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
DIRECTV Bags New NHL Deals: Stakes for Sports Fans

Updated Category News Views 308

NHL Fans, Strap in: DIRECTV Expands Its Lineup In a world where keeping up with your favorite team gets tougher each day, DIRECTV just lobbed a puck right into the net with their latest play. They've snagged a multi-year deal with the NHL for the Carolina Hurricanes, Columbus Blue Jackets, Minnesota Wild, and St. Louis Blues networks. It's a game changer, folks. If you...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 412

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
Firefox Champions Privacy with Iconic Internet Campaign

Updated Category News Views 106

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 130

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 288

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
CapCut's Role in AI-Assisted Small Biz Marketing

Updated Category News Views 131

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...

Continue Reading
Ivonescimab Promises New Hope for Advanced BTC Patients

Updated Category News Views 127

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 134

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading

Top 5 Most Recently Viewed Articles

Expanding Horizons: Future of IVD Contract Manufacturing

Updated Category News Views 117

The Growing Landscape of IVD Contract Manufacturing The in vitro diagnostics (IVD) contract manufacturing market is on the brink of significant expansion, anticipated to reach a staggering USD 39.74 billion by 2031. This growth represents a compounded annual growth rate (CAGR) of 11.60% from 2024 to 2031, driven chiefly by the needs of the healthcare industry to keep pace...

Continue Reading
Citi Upgrades AerCap Holdings Price Target to $117 Amid Strong Performance

Updated Category News Views 79

Citi Upgrades AerCap Holdings Price Target Citi has recently updated its outlook on AerCap Holdings (NYSE:AER), raising the price target to $117 from $113. This move reflects Citi's confident stance on the aircraft leasing company's financial health within the aviation sector. By reaffirming their buy rating, the firm signals strong expectations for AerCap's growth...

Continue Reading
LG Energy Solution Reports Strong Q2 2025 Financial Performance

Updated Category News Views 750

LG Energy Solution Achieves Remarkable Financial Milestones In a significant announcement, LG Energy Solution has revealed its performance for the second quarter of 2025, detailing impressive results that demonstrate the company's resilience and strategic focus on growth. With consolidated revenue of KRW 5.6 trillion and an operating profit of KRW 492.2 billion, the...

Continue Reading
Genpact Shines as a Leader in Sustainability Recognition

Updated Category News Views 264

Genpact's Sustainable Initiatives Gain Global Recognition Recently, Genpact (NYSE: G), an advanced technology services provider, received significant acclaim for its commitment to sustainability. Being featured in TIME's prestigious list of the World's Best Companies in Sustainable Growth for 2025 showcases their dedication to ethical business practices and innovation. A...

Continue Reading
Medical Express Ambulance Faces Data Breach Investigation

Updated Category News Views 344

Understanding the Data Breach Investigation Edelson Lechtzin LLP, a prominent class action law firm, is currently looking into data privacy concerns affecting customers of Medical Express Ambulance, Inc. (MedEx). MedEx has reported potential unauthorized access to its network, raising significant alarm regarding the safety of customer data. Medical Express Ambulance, Inc....

Continue Reading